[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rola Shadid\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100624372","single-implant-versus-two-implant-mandibular-overdentures-100624372",false,"NCT07408778","Single-implant Versus Two-implant Mandibular Overdentures","Patient-reported Outcomes and Masticatory Performance of Mandibular Overdentures Retained by One Parasymphyseal Implant or Two Implants: Randomized Clinical Trial","Inclusion Criteria:\n\n* Men and women ≥40 years.\n* ASA I-II; favorable general health or adequately controlled systemic disease (e.g., hypertension, diabetes).\n* Skeletal Class I relationship.\n* Completely edentulous mandible and maxilla.\n* Technically acceptable complete dentures in both jaws for ≥3 and ≤24 months; dissatisfaction limited to mandibular retention\u002Fstability.\n* Adequate anterior mandibular bone for implant ≥3.5×10 mm confirmed on CBCT; no bone augmentation needed.\n* Normal mucosal resilience (\\~2 mm displacement).\n* Implant sites healed ≥4 months since extraction.\n* Willingness to be randomized and attend follow-ups; written informed consent.\n* Primary stability target ≥25 N-cm.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease; neurodegenerative disease; osteoporosis requiring antiresorptives.\n* Chronic systemic antibiotics\u002Fsteroids; bleeding disorders; active cancer therapy; metabolic bone disease; HIV.\n* Investigational drug use within 30 days.\n* Alcohol dependence\u002Fillicit drug use; xerostomia (stimulated flow \\\u003C0.7 mL\u002Fmin).\n* Heavy smoking \\>20 cigarettes\u002Fday.\n* TMD\u002Forofacial pain; severe bruxism; moderate\u002Fsevere cognitive impairment.\n* Prior implant therapy.\n* Non-adherence risk or inability to attend longitudinal visits.\n* Insufficient prosthetic space for attachment housing: inter-arch vertical distance \\\u003C8.5 mm at parasymphyseal\u002Fcanine region.\n* Concurrent participation in another interventional study.\n* Erosive lichen planus or other significant oral mucosal disease; head-and-neck irradiation history.\n* Mandibular pathology on CBCT (e.g., cyst, tumor).\n* Ridge dimensions \\\u003C6 mm width or \\\u003C10 mm height at planned sites.\n* Active intraoral infection.","ALL","40 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled trial compares a mandibular overdenture retained by one implant placed in the parasymphyseal or canine region with a mandibular overdenture retained by two implants placed in the interforaminal region in completely edentulous adults. Primary outcomes are oral health-related quality of life, patient satisfaction, and masticatory performance measured by a two-color chewing gum mixing test, assessed at baseline before implant surgery and at 3, 6, and 12 months after overdenture insertion.",[26],"Edentulism",[28,29,30],"mandibular denture instability","poor denture retention","implant-retained overdenture","RECRUITING","2026-02-16",{"date":34,"type":35},"2026-02-17","ACTUAL",{"date":32,"type":35},{"date":38,"type":20},"2027-07",{"name":40,"class":41},"Rola Shadid","OTHER",""]